BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 24308016)

  • 1. Denosumab: a new treatment option for giant cell tumor of bone.
    Lewin J; Thomas D
    Drugs Today (Barc); 2013 Nov; 49(11):693-700. PubMed ID: 24308016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
    Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
    Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANKL, denosumab, and giant cell tumor of bone.
    Thomas DM
    Curr Opin Oncol; 2012 Jul; 24(4):397-403. PubMed ID: 22581354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Golden bullet-denosumab: early rapid response of metastatic giant cell tumor of the bone.
    Demirsoy U; Karadogan M; Selek Ö; Anik Y; Aksu G; Müezzinoglu B; Corapcioglu F
    J Pediatr Hematol Oncol; 2014 Mar; 36(2):156-8. PubMed ID: 24072245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
    Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
    BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
    Palmerini E; Chawla NS; Ferrari S; Sudan M; Picci P; Marchesi E; Leopardi MP; Syed I; Sankhala KK; Parthasarathy P; Mendanha WE; Pierini M; Paioli A; Chawla SP
    Eur J Cancer; 2017 May; 76():118-124. PubMed ID: 28324746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone.
    Lipplaa A; Dijkstra S; Gelderblom H
    Curr Opin Oncol; 2019 Jul; 31(4):329-335. PubMed ID: 30844887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab for the treatment of giant cell tumor of the bone.
    Brodowicz T; Hemetsberger M; Windhager R
    Future Oncol; 2015; 11(13):1881-94. PubMed ID: 26161925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Giant cell tumor of bone in childhood: clinical aspects and novel therapeutic targets.
    Federman N; Brien EW; Narasimhan V; Dry SM; Sodhi M; Chawla SP
    Paediatr Drugs; 2014 Feb; 16(1):21-8. PubMed ID: 24114694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.
    Thomas D; Henshaw R; Skubitz K; Chawla S; Staddon A; Blay JY; Roudier M; Smith J; Ye Z; Sohn W; Dansey R; Jun S
    Lancet Oncol; 2010 Mar; 11(3):275-80. PubMed ID: 20149736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study.
    Martin-Broto J; Cleeland CS; Glare PA; Engellau J; Skubitz KM; Blum RH; Ganjoo KN; Staddon A; Dominkus M; Feng A; Qian Y; Braun A; Jacobs I; Chung K; Atchison C
    Acta Oncol; 2014 Sep; 53(9):1173-9. PubMed ID: 24834795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical approach toward giant cell tumor of bone.
    van der Heijden L; Dijkstra PD; van de Sande MA; Kroep JR; Nout RA; van Rijswijk CS; Bovée JV; Hogendoorn PC; Gelderblom H
    Oncologist; 2014 May; 19(5):550-61. PubMed ID: 24718514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
    Sørensen AL; Hansen RL; Jørgensen PH
    Ugeskr Laeger; 2016 Sep; 178(36):. PubMed ID: 27593237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab: Excellent response of metastatic giant cell tumor of the bone.
    Ulas A; Bulent Akinci M; Silay K; Sendur MA; Sener Dede D; Yalcin B
    J BUON; 2015; 20(2):666-7. PubMed ID: 26011370
    [No Abstract]   [Full Text] [Related]  

  • 15. Giant cell tumour of bone in the denosumab era.
    van der Heijden L; Dijkstra PDS; Blay JY; Gelderblom H
    Eur J Cancer; 2017 May; 77():75-83. PubMed ID: 28365529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
    Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
    Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.
    Chawla S; Henshaw R; Seeger L; Choy E; Blay JY; Ferrari S; Kroep J; Grimer R; Reichardt P; Rutkowski P; Schuetze S; Skubitz K; Staddon A; Thomas D; Qian Y; Jacobs I
    Lancet Oncol; 2013 Aug; 14(9):901-8. PubMed ID: 23867211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
    Sano K; Suehara Y; Okubo T; Sasa K; Kurihara T; Akaike K; Kubota D; Torigoe T; Hasegawa N; Ishii M; Nakamura Y; Kim Y; Takagi T; Kaneko K; Hayashi T; Saito T
    J Orthop Surg (Hong Kong); 2020; 28(2):2309499020929786. PubMed ID: 32539628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
    Ueda T; Morioka H; Nishida Y; Kakunaga S; Tsuchiya H; Matsumoto Y; Asami Y; Inoue T; Yoneda T
    Ann Oncol; 2015 Oct; 26(10):2149-54. PubMed ID: 26205395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
    Reddy K; Ramirez L; Kukreja K; Venkatramani R
    J Pediatr Hematol Oncol; 2021 Mar; 43(2):e215-e218. PubMed ID: 31714440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.